ST 045849
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 471036

CAS#: 442665-87-4

Description: ST 045849 is an O-GlcNAc transferase (OGT) inhibitor, it can reduce proliferation and viability of prostate cancer cells in vitro.


Price and Availability

Size
Price

10mg
USD 385
Size
Price

50mg
USD 1250
Size
Price

ST 045849, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 471036
Name: ST 045849
CAS#: 442665-87-4
Chemical Formula: C23H27ClN2O3S
Exact Mass: 446.1431
Molecular Weight: 446.99
Elemental Analysis: C, 61.80; H, 6.09; Cl, 7.93; N, 6.27; O, 10.74; S, 7.17


Synonym: ST 045849, ST045849, ST-045849

IUPAC/Chemical Name: (Z)-3-(2-(adamantan-1-yl)ethyl)-2-((4-chlorophenyl)imino)-4-oxo-1,3-thiazinane-6-carboxylic acid

InChi Key: HLPZEZRNGAXCJH-LVWGJNHUSA-N

InChi Code: InChI=1S/C23H27ClN2O3S/c24-17-1-3-18(4-2-17)25-22-26(20(27)10-19(30-22)21(28)29)6-5-23-11-14-7-15(12-23)9-16(8-14)13-23/h1-4,14-16,19H,5-13H2,(H,28,29)/b25-22-

SMILES Code: O=C(C(S/C(N1CCC2(C3)CC4CC3CC(C4)C2)=N\C5=CC=C(Cl)C=C5)CC1=O)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1. Kim G.et al; Impact of protein O-GlcNAcylation on neural tube malformation in diabetic embryopathy; Sci Rep. 2017 Sep 11;7(1):11107. doi: 10.1038/s41598-017-11655-6.

2. Itkonen HM et al.; Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism; Oncotarget. 2016 Mar 15;7(11):12464-76. doi: 10.18632/oncotarget.7039.

3. Kim EJ et al.; Versatile O-GlcNAc transferase assay for high-throughput identification of enzyme variants, substrates, and inhibitors; Bioconjug Chem. 2014 Jun 18;25(6):1025-30. doi: 10.1021/bc5001774. Epub 2014 Jun 2

4. Victor V. Lima et al.; O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway; Cardiovasc Res. 2011 Feb 15; 89(3): 614–622.